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Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent, incurable myopathy, linked
to hypomethylation of D4Z4 repeats on chromosome 4q causing expression of the DUX4
transcription factor. However, DUX4 is difﬁcult to detect in FSHD muscle biopsies and it is
debatable how robust changes in DUX4 target gene expression are as an FSHD biomarker.
PAX7 is a master regulator of myogenesis that rescues DUX4-mediated apoptosis. Here,
we show that suppression of PAX7 target genes is a hallmark of FSHD, and that it is as
major a signature of FSHD muscle as DUX4 target gene expression. This is shown using
meta-analysis of over six FSHD muscle biopsy gene expression studies, and validated by
RNA-sequencing on FSHD patient-derived myoblasts. DUX4 also inhibits PAX7 from acti-
vating its transcriptional target genes and vice versa. Furthermore, PAX7 target gene
repression can explain oxidative stress sensitivity and epigenetic changes in FSHD. Thus,
PAX7 target gene repression is a hallmark of FSHD that should be considered in the
investigation of FSHD pathology and therapy.
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Facioscapulohumeral muscular dystrophy (FSHD) is a pre-valent inherited skeletal myopathy (12/100,000)1 that typi-cally presents during the second decade of life in males and
third decade in females. FSHD is characterised by an asymmetric,
descending skeletal muscle atrophy affecting speciﬁc muscle
groups, including the orbicularis occuli/orbis, the scapular ﬁxator
muscles, the biceps and latterly, the tibialis anterior and certain
other lower limb muscles2. Curiously, muscles such as the
quadriceps, diaphragm and deltoids are spared2, 3. FSHD is also
linked to retinal telangiectasia and sensorineural hearing loss,
pointing to more systemic mechanisms4, 5.
Genetically, FSHD is associated with hypomethylation of the
D4Z4 macrosatellite repeat at chromosome 4q35, coupled with a
permissive 4qA haplotype containing a polyadenylation signal in
the pLAM region distal to the ﬁnal D4Z4 repeat. Hypomethyla-
tion is caused either by D4Z4 repeat length truncation to between
1–10 D4Z4 units in FSHD1 (MIM 158900) (~ 95% of cases)6 or
by mutation in epigenetic modiﬁers in FSHD2 (MIM 158901),
particularly SMCHD17, but with DNMT3B also recently identiﬁed
in rare cases8. Each D4Z4 unit contains an open reading frame for
a retrogene termed double homeobox 4 (DUX4) (MIM 606009).
D4Z4 hypomethylation permits transcription of DUX4 from the
ﬁnal D4Z4 repeat, with DUX4 message stabilised by addition of a
polyadenylation tail by the signal in the ﬂanking DNA on a
permissive haplotype, and translated. The consensus is that such
DUX4 expression underlies pathology9 and DUX4 target gene
expression has been suggested as the major molecular signature in
FSHD10. However, detection of DUX4 is difﬁcult in FSHD muscle
biopsies and a consistent molecular biomarker of FSHD muscle
based on DUX4 expression has yet to be fully validated.
DNA binding, and so target gene selection, is deﬁned by the
homeodomains of DUX4, which display signiﬁcant amino-acid
sequence homology to the homeodomains of the transcription
factors PAX3 and PAX711. Given this homology, it has been
hypothesised that competitive inhibition of PAX3 and/or PAX7
by DUX4 may also contribute to FSHD pathology. PAX3 and
PAX7 are critical to development in the early embryo12, most
notably playing essential, non-redundant roles, in the generation
of the skeletal myogenic lineage13, and derivatives of the dorsal
neural ectoderm12. PAX3 and PAX7 are also highly homologous,
with 86% sequence similarity14 and are well conserved between
mouse and man. In adult, Pax7 is expressed in quiescent, acti-
vated and proliferating muscle satellite cells15, while the Pax3
locus is active in some satellite cells in certain muscles, such as the
diaphragm, and may be transiently expressed during
activation13, 16–18. Both genes promote cell survival and pro-
liferation, while preventing precocious differentiation15, 19. In
man, PAX7 is also detected in satellite cells20, 21 but little is
known about PAX3 in postnatal skeletal muscle. However,
mutations in PAX3 in man are associated with Waardenburg
syndrome22, a condition whose characteristics include high fre-
quency, sensorineural hearing loss, a symptom also reported in
FSHD.
In line with a competitive inhibition model, it has been
demonstrated that cytotoxicity caused by expression of DUX4 or
its murine ortholog mDUX is rescued by over-expression of Pax3
or Pax7 in murine myoblasts11, 23. We have recently shown in a
transgenic mouse model of FSHD that DUX4 levels rise during
the early phases of muscle regeneration in activated and pro-
liferating satellite cells, a phase when Pax7 is operating24. It has
also been shown that FSHD patient-derived cells express high
levels of DUX4 during a muscle progenitor phase characterised
by high levels of PAX3 and PAX7 during in vitro differentiation
of embryonic stem (ES) cells, providing another time point in
FSHD myogenic differentiation where competitive inhibition may
occur25. A more recent study of myogenic differentiation of ES
cells and induced pluripotent stem (iPS) cells from FSHD patients
showed that although PAX7 and DUX4 mRNA are found in a
myogenic progenitor phase, the two proteins are not present in
the same cell26. Interestingly, the frequency of co-expression of
PAX7 and DUX4 in FSHD cells was signiﬁcantly lower than
expected, indicating that some non-competitive inhibitory inter-
action between the two proteins may ensure such mutual exclu-
sivity26. PAX7 also drives long term epigenetic changes associated
with de-repression of gene expression, including DNA deme-
thylation27. Hence, inhibition of PAX7 by DUX4 in FSHD during
a muscle progenitor stage may result in a global suppression of
PAX7 transcriptional targets that persists in terminally differ-
entiated FSHD muscle. Such repression may represent a novel
biomarker of FSHD muscle, and deﬁne a new set of therapeutic
target genes. Examination of PAX7 target gene expression in
FSHD patient-derived samples is lacking, however, and so the
translational implications of this mechanism are unresolved.
Here, we adopt a meta-analysis approach across six indepen-
dent FSHD muscle biopsy studies to analyse several FSHD
molecular biomarkers based on DUX4 target gene expression,
and to compare them to a novel biomarker based on Pax7 target
gene repression. We ﬁnd that only the new biomarker based on
Pax7 target gene repression is consistently able to discriminate
FSHD from control skeletal muscle biopsies in every FSHD
biopsy data set, while the discriminatory power of DUX4 target
gene expression is limited to just two studies10, 28. The dis-
criminatory power of Pax7 target gene repression is veriﬁed via
RNA-seq of immortalised human myoblasts isolated from FSHD
patients and matched controls. We also show that the Pax7 target
genes repressed in FSHD are enriched for factors that suppress
the HIF1α-mediated hypoxic response, indicating over-activation
of HIF1α in FSHD as a putative pathomechanism driving oxi-
dative stress sensitivity, as we previously suggested29. Lastly, co-
expression of DUX4 and Pax7 results in repression of their
respective target genes, conﬁrming mutual target gene inhibition
between these two transcription factors. Overall, our ﬁndings
demonstrate that Pax7 target gene repression is at least as strong a
signature in FSHD skeletal muscle as DUX4 target gene over-
expression. Thus, Pax7 target genes should be considered in the
investigation of pathology and design of therapies in FSHD.
Results
DUX4 target gene expression as an FSHD biomarker. Tran-
scriptomic biomarkers of FSHD muscle are important both for
understanding molecular processes perturbed in pathology and
for monitoring therapeutic responses in clinical trials3. In recent
years, a number of transcriptomic biomarkers for identifying
FSHD muscle biopsies have been proposed, notably the biopsy-
derived 15 gene signature described by Rahimov et al.3, and the
114 gene signature derived from human myoblasts over-
expressing DUX4, described by Yao et al.10. Outside of a small
number of samples, however, these biomarkers have received little
validation.
We identiﬁed six independent transcriptomic studies proﬁling
FSHD muscle biopsies alongside suitable controls (ﬁve micro-
array studies totalling 82 FSHD and 82 controls and one RNA-
seq study with 15 FSHD and 8 control samples)3, 10, 28, 30–32 and
assessed the discriminatory capacity of the Rahimov et al.3 and
Yao et al.10 biomarkers via meta-analysis (Fig. 1). Meta-analysis
over ﬁve independent data sets revealed that neither biomarker
could reliably discriminate FSHD from control samples. Inter-
estingly however, both signatures were able to discriminate
between FSHD and control muscle biopsies on one microarray
data set independent of their discovery data sets, namely that
described by Tasca et al.28. Unlike the other studies, this data set
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proﬁled affected FSHD muscle as conﬁrmed by magnetic
resonance imaging (MRI), indicating that an MRI guided muscle
biopsy approach may be optimal for identifying tissue displaying
molecular changes associated with FSHD.
The DUX4-based biomarker of Yao et al.10 was derived from
RNA-seq data of two human myoblast samples over-expressing
DUX4, compared to two qualitatively different controls, one of
which was contaminated and contained reads from a DUX4-
expressing sample33. Hence it is unclear how representative the
Yao et al.10 biomarker is of DUX4 expression. Unfortunately, the
only data set proﬁling FSHD muscle biopsies by RNA-seq was
also produced by Yao et al.10 and our other validation data sets
were proﬁled by microarray. Therefore, it is also unclear whether
failure of these genes to discriminate FSHD status is due to DUX4
target genes not being a biomarker, or due to differences in the
technology platforms used, namely microarray vs. RNA-seq.
To address these issues, we derived two further DUX4 over-
expression signatures from two independent human myoblast
DUX4 over-expression studies. The ﬁrst signature was derived
from a recent RNA-seq data set proﬁling human myoblasts over-
expressing DUX4 for 8 h via a doxycycline inducible promotor
against suitable controls, as described by Choi et al.34. We
identiﬁed 212 transcripts that were signiﬁcantly upregulated in
DUX4-expressing samples (FDR< 0.05, log FC> 2, Supplemen-
tary Data 1). The Choi et al.34 DUX4 target gene signature was
signiﬁcantly elevated in FSHD samples from the Yao et al.10
RNA-seq muscle biopsy data set. However, we found no
signiﬁcant difference in Choi et al.34 DUX4 target levels between
FSHD and control samples in any of the ﬁve microarray data sets
or on meta-analysis (Fig. 2a–b).
A second DUX4 signature was derived from a microarray
data set published by Geng et al.35, proﬁling DUX4
lentivirus transduced human myoblasts after 24 h against suitable
controls35. We identiﬁed 165 transcripts that were signiﬁcantly
upregulated in DUX4-expressing samples (FDR< 0.05,
log FC> 2, Supplementary Data 2). The Geng et al.35 DUX4
target gene signature was signiﬁcantly upregulated on the FSHD
muscle biopsy samples from the Yao et al.10 RNA-seq data set.
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Fig. 1 Reported FSHD biomarkers do not validate on most published FSHD muscle biopsy gene expression data sets. a Box plot conﬁrms that the Yao
et al.10 DUX4 114 target gene signature validates as a biomarker on the RNA-seq FSHD muscle biopsy data set published by Yao et al.10. The box
represents the interquartile range (IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)). ‘‘o’’ represents data
points greater than 1.5 IQR from the median, n= 15 FSHD and n= 8 control muscle biopsies. b A forest plot displays the results of meta-analysis of the
discriminatory power of the Yao et al.10 DUX4 target gene signature across ﬁve published microarray FSHD muscle biopsy data sets (in total n= 82 FSHD
and n= 82 control muscle biopsies). The differential scores (FSHD score minus control score) alongside 95% conﬁdence intervals are provided. c A box
plot conﬁrms that the Rahimov et al.3 FSHD 15 gene biomarker validates as a biomarker on the microarray FSHD muscle biopsy discovery data set
published by Rahimov et al.3. The box represents the interquartile range (IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max
(observed value)). ‘‘o’’ represents data points greater than 1.5 IQR from the median, n= 26 FSHD and n= 24 control muscle biopsies. d A forest plot
displays the results of meta-analysis of the discriminatory power of the Rahimov et al.3 FSHD biomarker across four published microarray and one RNA-seq
FSHD muscle biopsy data sets (in total n= 71 FSHD and n= 66 control muscle biopsies). The differential scores (FSHD score minus control score)
alongside 95% conﬁdence intervals are provided. Neither biomarker is able to discriminate FSHD from control samples on meta-analysis. However, both
are able to discriminate on the Tasca et al.28 MRI-guided muscle biopsy microarray data set. For single studies a two-tailed Wilcoxon U-test was performed
to assess signiﬁcance, while a Fisher’s combined test was employed for overall assessment: either the p-value is given, or an asterisk denotes p< 0.05
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Moreover, across the ﬁve microarray FSHD studies, although no
individual study showed statistically signiﬁcant elevation of
DUX4 target gene expression, all studies showed a positive trend
towards this. On meta-analysis, we identiﬁed a small, but
signiﬁcant, upregulation of DUX4 targets in FSHD samples
(Fisher’s combined test p= 0.045, Fig. 2c–d).
As DUX4 suppresses MyoD11, 24 we also evaluated expression
of MyoD target genes identiﬁed by de la Serna et al.36 in the ﬁve
FSHD microarray studies. Although no individual data set was
signiﬁcant, there was a trend towards repression of MyoD target
genes across microarray studies of FSHD muscle biopsies, but this
was also not signiﬁcant on meta-analysis (Supplementary Fig. 1)
Our results indicate that DUX4 target gene expression is a
weak, but signiﬁcant, biomarker of FSHD status but points to a
lack of compatibility between RNA-seq and microarray studies for
evaluating DUX4 transcriptional target genes. Despite overlap
between the three DUX4 signatures (28 genes shared between
Geng et al.35 and Choi et al.34, 45 between Yao et al.10 and Geng
et al.35 and 29 between Choi et al.34 and Yao et al.10), we see that
RNA-seq-derived DUX4 upregulated target genes are only capable
of discriminating FSHD biopsies from controls, if the biopsies
were also proﬁled by RNA-seq. In contrast, microarray-based
DUX4 upregulated target genes show discriminatory power on
both microarray (on meta-analysis) and RNA-seq data sets (Figs. 1
and 2). This is likely due to differences in coverage and dynamic
range across the two technologies and is a consideration when
evaluating DUX4 transcriptional target genes on FSHD samples.
PAX7 target gene repression hallmarks FSHD skeletal muscle.
We next considered repression of PAX7 target genes as a bio-
marker of FSHD muscle. To derive a set of PAX7 target genes, we
assayed primary murine satellite cell-derived myoblasts over-
expressing Pax7, a dominant negative Pax7 fusion protein,
comprising the DNA binding domains of Pax7 and the engrailed
repressor domain (Pax7-ERD)15 and a control retroviral con-
struct. PAX7 is highly conserved between mouse and man with
97% amino-acid sequence homology13, hence a conserved set of
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Fig. 2 Novel DUX4 target gene signatures only discriminate some FSHD muscle biopsy gene expression data sets from controls. a A box plot demonstrates
that the Choi et al.34 RNA-seq-based 212 DUX4 target gene signature validates as a biomarker on the RNA-seq FSHD muscle biopsy data set published by
Yao et al.10. The box represents the interquartile range (IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)).
‘‘o’’ represents data points greater than 1.5 IQR from the median, n= 15 FSHD and n= 8 control muscle biopsies. b A forest plot displays the results of
meta-analysis of the discriminatory power of the Choi et al.34 DUX4 target gene signature across ﬁve published microarray FSHD muscle biopsy data sets
(in total n= 82 FSHD and n= 82 control muscle biopsies). The differential scores (FSHD score minus control score) alongside 95% conﬁdence intervals
are provided. The Choi et al.34 DUX4 target gene signature is not a signiﬁcant biomarker on any microarray data set nor on meta-analysis. Note: in the Choi
et al.34 study, target genes were analysed after 8 h of DUX4 induction. c A box plot demonstrates that the Geng et al.35 microarray based 165 DUX4 target
gene signature validates as a biomarker on the RNA-seq FSHD muscle biopsy data set published by Yao et al.10. The box represents the interquartile range
(IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)). ‘‘o’’ represents data points greater than 1.5 IQR from the
median, n= 15 FSHD and n= 8 control muscle biopsies. d A forest plot displays the results of meta-analysis of the discriminatory power of the Geng et al.35
DUX4 target gene signature across ﬁve published microarray FSHD muscle biopsy data sets (in total n= 82 FSHD and n= 82 control muscle biopsies). The
differential scores (FSHD score minus control score) alongside 95% conﬁdence intervals are provided. The Geng et al.35 DUX4 target gene signature is not
a signiﬁcant biomarker on any individual microarray data set, however, it is signiﬁcant on meta-analysis. For single studies a two-tailed Wilcoxon U-test
was performed to assess signiﬁcance, while a Fisher’s combined test was employed for overall assessment: either the p-value is given, or an asterisk
denotes p< 0.05
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target genes is expected. We assayed gene expression via micro-
array to facilitate compatibility with the publically available FSHD
muscle biopsy data sets. Microarray data were pre-processed and
normalised as described in Methods. Hierarchical clustering and
principal component analysis conﬁrmed reproducibility of the
transcriptional landscapes induced by the PAX7 constructs and
close clustering of replicates.
Unlike DUX4, which is a potent transcriptional activator24, 29,
PAX7 likely modulates transcription in more complex ways12.
Hence, to derive a biomarker of Pax7 expression in murine
satellite cells, rather than focus only on the most strongly induced
target genes, we performed differential expression analysis to
derive a set of 311 upregulated target genes (deﬁned as induced by
PAX7 over-expression and suppressed by PAX7-ERD) and a set
of 290 downregulated target genes (deﬁned as suppressed by
PAX7 over-expression and induced by PAX7-ERD) (Supplemen-
tary Data 3). A biomarker of PAX7 was then deﬁned from
consideration of the ratio of mean upregulated to downregulated
target gene expression in a given sample (see Methods). To
validate this ratio as a biomarker of PAX7, we evaluated it on an
independent microarray dataset describing Pax7 retroviral over-
expression in primary murine satellite cells alongside control
retrovirus in triplicate14. Our PAX7 biomarker demonstrated
signiﬁcantly higher values on samples over-expressing Pax7 in
this independent data set, so conﬁrming its validity (Supplemen-
tary Fig. 2).
To evaluate the functional relevance of PAX7 target genes to
FSHD pathology, we performed gene set enrichment analysis
(GSEA) of activated and repressed target genes of
PAX7 separately against the Molecular Signatures database
(MSigDB)37, 38. The top 100 enriched gene sets for the PAX7
targets are presented in Supplementary Data 4 and 5. To reﬁne
our search we identiﬁed gene sets which displayed inverse
enrichments across activated and repressed targets (Fig. 3a).
PAX7 is associated with repression of a hypoxia gene set.
Importantly of 48 hypoxia gene sets in MSigDB37, 38, only one
was identiﬁed, describing genes upregulated or downregulated by
over-expression of an active form of HIF1α39. We have previously
implicated over-activation of HIF1α as a putative mechanism for
oxidative stress sensitivity in FSHD29. Another gene set repressed
by PAX7 is EZH2 target genes (Fig. 3a). EZH2 is a critical
component of the polycomb repressor complex 2 (PRC2), which
has been associated with perturbed methylation in FSHD40, 41.
Thus PAX7 target genes are enriched for pathways previously
identiﬁed in FSHD molecular pathology.
We next evaluated our PAX7 biomarker on the six FSHD
muscle biopsy data sets. We found that the levels of PAX7 target
genes were signiﬁcantly repressed in FSHD muscle biopsy
samples proﬁled by RNA-seq (Fig. 3b). Importantly, PAX7 target
gene repression was also found to be a signiﬁcant biomarker
of FSHD status in each of the ﬁve microarray FSHD muscle
biopsy studies independently, leading to a highly signiﬁcant
repression of PAX7 target genes on meta-analysis (Fisher’s
combined test p= 3.5 × 10−9, Fig. 3c).
To conﬁrm that PAX7 target gene repression is speciﬁc to
FSHD and not attributable to general muscle wasting, we
identiﬁed four published microarray studies proﬁling Duchenne
muscular dystrophy (DMD) muscle biopsies alongside matched
controls31, 42, 43. Meta-analysis revealed no consistent signiﬁcant
difference in PAX7 target gene expression between DMD muscle
and controls (Supplementary Fig. 3).
The PAX7 and DUX4 biomarkers were derived differently, so
it is necessary to consider how the results would change if this
were not the case. Firstly, if repressed DUX4 targets are combined
with the induced targets to construct a biomarker of DUX4
analogous to our derivation of the PAX7 biomarker, DUX4 target
genes are lost as a discriminator of FSHD status. This indicates
that only robustly upregulated DUX4 targets have discriminatory
power in FSHD and that suppressed targets introduce noise that
masks this signal. Conversely, if we separately consider the
upregulated or downregulated target genes of PAX7, rather than
together as a biomarker of PAX7 (analogous to the DUX4
biomarker), we see that upregulated target genes are signiﬁcantly
repressed in FSHD microarray samples on meta-analysis, while
downregulated target genes are signiﬁcantly over-expressed,
conﬁrming that both activated and suppressed PAX7 target genes
are perturbed in FSHD. However, the upregulated or down-
regulated target genes alone are unable to discriminate between
FSHD and control muscle biopsies on the RNA-seq data set
(Supplementary Fig. 4).
This cross comparison demonstrates that the biomarker
construction which maximises DUX4 target gene discriminatory
power in FSHD focuses only on upregulated targets, while that
which maximises PAX7 target gene discriminatory power utilises
both upregulated and downregulated target genes.
To conﬁrm that our PAX7 biomarker does not discriminate
FSHD status from control by chance, we performed a resampling
procedure, selecting 1000 random gene sets of equivalent size to
both the upregulated and downregulated PAX7 target gene sets.
For each randomisation, we deﬁned a biomarker analogously to
the PAX7 biomarker using the ratio of upregulated to down-
regulated target genes and evaluated its capacity to discriminate
FSHD and control muscle biopsies on meta-analysis across the
ﬁve FSHD microarray muscle biopsy data sets. None of the
random biomarkers were able to signiﬁcantly discriminate FSHD
from control samples on meta-analysis (Supplementary Fig. 5),
hence the probability that PAX7 target gene repression in FSHD
is attributed to chance is less than 1/1000.
PAX7 or DUX4 target genes form equivalent FSHD bio-
markers on RNA-seq data. To compare the discriminatory
capacity of our PAX7 target gene biomarker against the various
DUX4 target gene biomarkers, we employed a receiver operating
characteristic (ROC) approach. Given the data compatibility
issues explored above, we considered the microarray and RNA-
seq muscle biopsy data separately. An impact of this is that
analysis over the RNA-seq data is underpowered relative to the
microarray data due to large differences in sample size (RNA-seq
data: 8 controls, 15 FSHD; pooled microarray data: 82 controls,
82 FSHD), and such a discrepancy should be taken into account
on data interpretation.
Considering the microarray data, the only signiﬁcant biomar-
kers on meta-analysis were our PAX7 target gene repression
signature and the robustly upregulated DUX4 targets described
by Geng et al.35 while Choi et al.34 and Yao et al.10 failed to reach
signiﬁcance. Both biomarkers were computed for each sample on
each microarray study independently and z-normalised within
each study to ensure identically distributed predictors, studies
were then pooled for ROC analysis. We found that PAX7 target
gene repression signiﬁcantly outperformed DUX4 target expres-
sion as a classiﬁer of FSHD status (Pax7 AUC= 0.81, DUX4
AUC= 0.59, DeLong’s test: p< 5.7 × 10−6, Fig. 4a), indicating
that in microarray data, PAX7 target gene repression is a more
robust signature of FSHD skeletal muscle than DUX4 target gene
expression.
Considering the smaller RNA-seq data set, all three DUX4
upregulated target gene signatures (Geng et al.35, Choi et al.34 and
Yao et al.10), as well as our PAX7 target gene repression signature,
proved to be signiﬁcant biomarkers of FSHD status. Though the
Yao et al.10 signature demonstrated a slightly higher AUC on
the RNA-seq samples, than the Pax7 biomarker (Yao et al.10
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AUC= 0.85, Geng et al.35 AUC= 0.79, Choi et al.34 AUC= 0.78,
PAX7 AUC= 0.78, Fig. 4b), DeLong’s test revealed no signiﬁcant
differences between the discriminatory power of any of the
biomarkers on this data set. Thus PAX7 target gene repression is
at least as major a signature of FSHD skeletal muscle as DUX4
target gene expression.
PAX7 or DUX4 target genes are equivalent biomarkers on
FSHD myoblasts. As muscle biopsies do not represent a pure
myogenic population of cells, we next investigated our PAX7 or
DUX4 target gene biomarkers in FSHD patient-derived myoblast
cell lines. We performed RNA-sequencing on immortalised human
myoblasts isolated from three independent FSHD patients alongside
matched controls44, 45. One of the FSHD patients considered is
mosaic for the FSHD genotype and multiple clones are available45,
of which we considered ﬁve. These clones are isogenic with excep-
tion of the D4Z4 region, which is truncated to three repeats in clones
54–12, 54-2 and 54-A5 (an FSHD genotype), whereas clones 54-6
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Fig. 3 PAX7 target gene signature is a robust hallmark of FSHD skeletal muscle. a Gene set enrichment analysis was performed separately for activated and
repressed targets of PAX7 against the Molecular Signatures database (MSigDB)37, 38. Gene sets in MSigDB are frequently partitioned into ‘‘genes
upregulated in phenotype’’ and ‘‘genes downregulated in phenotype’’. If such opposing gene sets were inversely signiﬁcantly enriched across activated and
repressed PAX7 targets (as assessed by Fisher’s exact test), they were considered robust. A bar plot displays the −log10 (enrichment p-value) for PAX7
robust gene sets. A horizontal green line denotes p= 0.05. UP and DOWN on the x-axis refers to the partition of labeled gene sets into genes positively
and negatively associated with the gene set respectively. PAX7 targets are enriched for repression of a HYPOXIA gene set, which speciﬁcally describes
genes upregulated and downregulated following over-expression of a constitutively active form of HIF1α. Another gene set affected by PAX7 repression is
EZH2 target genes. b A box plot demonstrates that the PAX7 target gene signature derived from 311 upregulated target genes and 290 downregulated
target genes, validates as a biomarker on the RNA-seq FSHD muscle biopsy data set published by Yao et al.10. The box represents the interquartile range
(IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)). ‘‘o’’ represents data points greater than 1.5 IQR from the
median, n= 15 FSHD and n= 8 control muscle biopsies. The two-tailed Wilcoxon U-test p-value is given. c A forest plot displays the results of meta-
analysis of the discriminatory power of the PAX7 target gene signature across ﬁve published microarray FSHD muscle biopsy data sets (in total n= 82
FSHD and n= 82 control muscle biopsies). The differential scores (FSHD score minus control score) alongside 95% conﬁdence intervals are provided. Our
PAX7 target gene signature is a signiﬁcant biomarker on every individual FSHD muscle biopsy data set, and is strongly signiﬁcant on meta-analysis. For
single studies, a two-tailed Wilcoxon U-test was performed to assess signiﬁcance, while a Fisher’s combined test was employed for overall assessment:
*denotes p< 0.05, **denotes p< 0.01 and ***denotes p< 0.001
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and 54-A10 have 13 repeats (a ‘‘healthy’’ number). The two further
FSHD patient cell lines considered were the 12Abic and 16Abic
immortalised myoblasts obtained from the UMMS Wellstone centre
for FSHD, Worcester, USA, alongside sibling-matched controls44.
RNA-sequencing was performed in triplicate on conﬂuent myoblasts
for each cell line, giving a total of 15 FSHD samples (three patients
corresponding to ﬁve lines in triplicate) and 12 control samples
(three individuals corresponding to four lines in triplicate).
Our PAX7 biomarker, alongside the DUX4 target gene
signatures (Yao et al.10, Choi et al.34 and Geng et al.35), were
computed for each sample and scores for each patient and
matched control were z-normalised and pooled for analysis. We
found that our PAX7 biomarker, the Yao et al.10 and Geng et al.35
DUX4 target gene signatures were all signiﬁcant discriminators of
FSHD status (Wilcoxon signed rank test p< 0.05, Fig. 5a–d), in
line with our results from the muscle biopsy RNA-seq data, but
the Choi et al.34 DUX4 target gene signature was not (Fig. 5a).
ROC curve analysis demonstrated that there was no signiﬁcant
difference between the discriminatory power of our PAX7
biomarker and the DUX4 biomarkers on FSHD patient cell lines
(De-Long’s test p> 0.05, Fig. 5e). This provides further evidence
that PAX7 target gene repression is at least as major a signature as
DUX4 target gene expression in FSHD skeletal muscle.
PAX7 and DUX4 mutually inhibit target gene activation.
Having established that PAX7 target genes are repressed in FSHD
skeletal muscle, we next investigated if DUX4 could lead to
repression of PAX7 transcriptional target genes, as suggested by
the homology between their homeodomains11. A reporter con-
struct assay was performed on human embryonic kidney (HEK-
293) or NIH-3T3 cells transfected with plasmids encoding DUX4,
Pax7, both DUX4 and Pax7 together, dominant negative DUX4
(DUX4-ERD)29 or PAX7 (Pax7-ERD)15, and GFP as a control. To
measure the ability of PAX7 to activate its transcriptional targets,
we measured activity of the p34 reporter construct, consisting of
concatermerised PAX3/7-binding sites driving thymidine kinase-
nlacZ15, along with endogenous expression of the PAX7 target
gene SELP14. To quantify DUX4 activity, we used DUX4 reporter
constructs RFPL4B-luc or ZSCAN4-luc controlling a luciferase
reporter gene46 and also measured endogenous expression of the
DUX4 target genes ZSCAN4, RFPL4B, MBD3L2 and TRIM48.
PAX7 robustly elevated p34 reporter activity, as expected.
Interestingly, DUX4 also increased p34 reporter activity, but to a
smaller extent than PAX7. Strikingly both DUX4 and PAX7
proteins together resulted in no change of p34 reporter activity,
with the level unaltered from that achieved by transfection of
control GFP-encoding plasmid (Fig. 6a). Reverse transcription
quantitative PCR (RT-qPCR) of PAX7 target gene SELP also
conﬁrmed its activation by PAX7, but when both DUX4 and PAX7
were present together, transcription of SELP dropped to control
levels (Fig. 6b). Thus, while DUX4 can bind and activate the PAX7
reporter gene, when DUX4 is present with PAX7, the effect is to
repress activation of PAX7 transcriptional target genes. Levels of
PAX7 target gene activation achieved with DUX4 and PAX7 co-
expression are lower than achieved by either PAX7 or DUX4 alone,
implying that the mechanism by which DUX4 represses PAX7
transcriptional target gene activation may encompass mechanisms
in addition to competitive inhibition of DNA-binding.
Performing reciprocal experiments using DUX4 reporters, we
found that while DUX4 activated both the RFPL4B-luc or
ZSCAN4-luc reporters, PAX7 did not activate either DUX4-
reporter (Fig. 6c, d). As observed with the PAX7 reporter assay,
expression of both PAX7 and DUX4 proteins together, signiﬁ-
cantly reduced DUX4 reporter activity compared to DUX4 alone,
and back to control levels with the RFPL4B-luc reporter (Fig. 6d).
These ﬁndings were conﬁrmed via RT-qPCR of endogenous
DUX4 transcriptional target genes, which showed that DUX4
induced expression of ZSCAN4, RFPL4B, MBD3L2 and TRIM48,
while both DUX4 and PAX7 together failed to increase transcript
levels of these DUX4 target genes to the same level as DUX4 alone,
and in 3 out of 4 cases, not above control levels (Fig. 6e–h).
Therefore, inhibition between DUX4 and PAX7 proteins is
reciprocal, whereby co-expression of PAX7 and DUX4 acts to
suppress the respective transcriptional target genes of both DUX4
and PAX7.
Discussion
Here, we demonstrate that PAX7 target gene repression is a
hallmark of FSHD skeletal muscle. Moreover, it is a superior
FSHD biomarker to DUX4 target gene expression across micro-
array data sets, and at least as major a signature of FSHD skeletal
muscle when considering RNA-seq data.
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Fig. 4 PAX7 target gene repression is an equivalent FSHD biomarker to
DUX4 target gene expression. a A ROC curve compares the discriminatory
power of our PAX7 biomarker with the DUX4 target gene signature that we
derived from Geng et al.35, across ﬁve microarray data sets (in total n= 82
FSHD and n= 82 control muscle biopsies). De-Long’s test p-value is given
and demonstrates that the PAX7 biomarker is a signiﬁcantly better
discriminator of FSHD status. b A ROC curve compares the discriminatory
power of our PAX7 biomarker with the DUX4 target gene signatures that
we derived from Geng et al.35 and Choi et al.34 and that described in Yao
et al.10 across the RNA-seq data set of n= 15 FSHD and n= 8 control
muscle biopsies. De-Long’s test reveals no signiﬁcant differences in the
discriminatory power of these four biomarkers
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DUX4 is currently the leading candidate gene in FSHD
molecular pathology9. Recently, it has been suggested that DUX4
target gene expression is also the major molecular signature in
FSHD skeletal muscle43. This has led to an acceleration of
investigations into DUX4 target genes in FSHD, which are pro-
apoptotic and suppress myogenic progression11, 24, 29, 47–49. In
addition to these DUX4 focused studies, others have compared
FSHD and control skeletal muscle in an hypothesis free manner.
Using this approach, we and others, have revealed FSHD mole-
cular mechanisms, which may not be direct consequences of
DUX4 target gene expression, such as HIF1α target gene
activation29, 50 and epigenetic alterations in PCR2 genes41. Such
mechanisms are an important line of investigation into FSHD
pathology and therapeutics, but may not be fully understood by
investigation of DUX4 target genes alone.
The idea that DUX4 and PAX7 protein may mutually inhibit
the activation of their respective transcriptional target genes was
originally proposed by Bosnakovski et al.11 and was based on
sequence similarity between the homeodomains of the two
transcription factors. This model provides an alternative
mechanism by which DUX4 may drive molecular changes in
FSHD. However, besides the demonstration that Pax7 can
mitigate DUX4 driven apoptosis in murine myoblasts11, 23, the
role of PAX7 in human FSHD pathology has been little investi-
gated. Recently, it has been demonstrated by several groups,
including our own, that DUX4 and PAX7 mRNA are co-
expressed in muscle progenitor cells from FSHD patients25 and
during regeneration in an FSHD mouse model24, providing
opportunity for the proteins to interact. A recent study investi-
gating myogenic differentiation of ES and iPS cells derived from
FSHD and control patients, reported that both PAX7 and DUX4
mRNA expression could be detected both during a myogenic
precursor phase and in myotubes26. However, immuno-
ﬂuorescence suggested that PAX7 and DUX4 protein were not
localised to the same cells. Although embryonic muscle is usually
unaffected in FSHD9, it is interesting that the authors could not
ﬁnd cells containing both PAX7 and DUX4. The statistically
signiﬁcant low frequency of co-expression indicates that PAX7
and DUX4 protein may interact to cause mutual exclusivity26,
resulting in repression of PAX7 transcriptional target genes in
FSHD muscle, as we report.
Here, we show that when PAX7 and DUX4 are present in the
same cell, the effect is the mutual inhibition of the respective
transcriptional target genes of both proteins. Moreover,
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Fig. 5 PAX7 and DUX4 target gene biomarkers validate on FSHD myoblast gene expression data sets. Box plots show the a Choi et al.34, b Yao et al.10 and
c Geng et al.35 DUX4 target gene signatures and d our PAX7 biomarker, computed for ﬁve FSHD patient lines and four matched control lines corresponding
to three patients and controls RNA-sequenced in triplicate (in total n= 15 FSHD and n= 12 Control). In line with previous ﬁndings, PAX7 repression and
DUX4 expression as assessed by the Yao et al.10 and Geng et al.35 DUX4 target signatures are signiﬁcant biomarkers of FSHD status. The Choi et al.34
DUX4 target gene biomarker is not a signiﬁcant discriminator of FSHD status, where target genes were identiﬁed after 8 h of DUX4 induction. The box
represents the interquartile range (IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)). ‘‘o’’ represents data
points greater than 1.5 IQR from the median. The two-tailed Wilcoxon U-test p-value is given. e A ROC curve compares the discriminatory power of our
PAX7 biomarker with the Geng et al.35, Choi et al.34 and Yao et al.10 DUX4 target gene signatures across the RNA-seq data set of FSHD and control
immortalised myoblasts. De-Long’s test reveals no signiﬁcant differences in the discriminatory power of these three DUX4 and one PAX7 biomarkers
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Fig. 6 Co-expression of PAX7 and DUX4 causes suppression of the transcriptional activity of both proteins. HEK-293 or NIH-3T3 cells were transfected
with plasmids encoding DUX4, Pax7, DUX4 and Pax7, or dominant negative-version DUX4-ERD, or Pax7-ERD. a The ability of PAX7 to activate its
transcriptional target genes was measured via the p34 plasmid driving lacZ, co-transfected with the constructs listed above, together with a control RSV
luciferase plasmid as a transfection normaliser, into NIH-3T3 cells. Reporter gene intensities were measured using a Glomax-Multi + plate reader and
normalised to RSV luciferase. PAX7 activated the p34 PAX7 reporter construct, but both PAX7 and DUX4 together suppressed activity of this PAX7
reporter compared to PAX7 alone. b RT-qPCR for PAX7 transcriptional target gene SELP conﬁrms that co-expression of Pax7 and DUX4 suppresses the
activation of this endogenous PAX7 transcriptional target compared to PAX7 alone, in HEK-293. The ability of DUX4 to activate its transcriptional target
genes was measured via two separate DUX4 reporter constructs: c ZSCAN4-luc and d RFPL4B-luc, both controlling a luciferase reporter gene, co-
transfected with DUX4 and/or Pax7 constructs, or DUX4-ERD or GFP, together with a RSV lacZ as a transfection normaliser, into HEK-293. Reporter gene
intensities were measured using a Glomax-Multi + plate reader and normalised to β-galactosidase activity. While DUX4 activated both DUX4 reporters,
both PAX7 and DUX4 together, suppressed activity of these DUX4 reporters compared to DUX4 alone. RT-qPCR for DUX4 endogenous transcriptional
target genes. e TRIM48, f ZSCAN4, g RFPL4B and hMBD3L2 conﬁrms that the presence of both PAX7 and DUX4 together suppresses activation of all these
endogenous DUX4 transcriptional target genes compared to the levels achieved by DUX4 alone in HEK-293 cells. Boxes represents the interquartile range
(IQR), with the median indicated by a line. Whiskers denote min (1.5*IQR, max (observed value)). For bar graphs, error bars denote standard error of the
mean, n= 3 or 4 for each cell line, ANOVA revealed signiﬁcant intensity differences, post hoc unpaired two tailed t-tests were employed to assess
signiﬁcant pairwise differences: *denotes p< 0.05, and n.s. denotes non-signiﬁcance of pairwise t-tests
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suppression of PAX7 transcriptional target genes when DUX4
and PAX7 are co-expressed is greater than would be expected
under a competitive inhibition model. There are several possible
mechanisms by which DUX4 and PAX7 proteins may interact to
cause a suppression of PAX7 target genes in FSHD in addition to
competitive inhibition. One is a direct protein–protein interac-
tion, such as dimerization, which could disrupt target gene acti-
vation. Since PAX3 and PAX7 bind DNA as cooperative
dimers14, 51 via motifs in the homeobox domain52, the homeobox
domains of DUX4 may interfere with such dimerization to dis-
rupt DNA-binding.
DUX4-mediated suppression of PAX7 transcriptional target
genes, coupled with the report that PAX7 target genes can induce
long-term epigenetic changes that persist in differentiated mus-
cle27, may explain our ﬁnding that PAX7 target gene repression is
a feature of FSHD skeletal muscle. Such repression may directly
contribute to FSHD molecular pathology. Indeed, we show here
that PAX7 target gene repression is associated with over-
expression of EZH2 target genes, an important pathway in epi-
genetic modiﬁcation in skeletal muscle. EZH2 is a well-known
epigenetic transcriptional repressor and component of PRC2
complex, which plays critical roles in development and cancer53.
It has been shown that EZH2 is enriched at the D4Z4 region in
healthy control primary myocytes, but not in FSHD patient-
derived cells, contributing to epigenetic de-repression of DUX4 in
FSHD41. Our data suggests that DUX4 inhibition of PAX7,
resulting in perturbation of EZH2 targets, may also contribute to
epigenetic de-repression of DUX4 in FSHD54.
We further show that PAX7 target gene repression is
associated with over-expression of HIF1α-mediated hypoxic
response genes. Oxidative stress sensitivity is a well-known
phenotype of FSHD myoblasts54, 55, however, the precise
mechanism is unclear. Studies focusing on DUX4 target gene
expression have implicated perturbation of the glutathione redox
pathway11, while studies investigating FSHD patient-derived
tissue in an unbiased manner have implicated HIF1α
transcriptional dysregulation29, 50. Our results suggest that this
latter mechanism could be attributed to DUX4-mediated
inhibition of PAX7 target genes.
Mechanistically, HIF1α plays a complex role in cellular
response to hypoxia and can be either pro- and anti-apoptotic,
depending on oxygen levels, cell type and experimental set-up56.
In normoxia, HIF1α undergoes proteasomal degradation, fol-
lowing oxygen-dependent ubiquitination by the Von Hippel
Lindau tumour suppressor57. Hypoxia thus results in nuclear
accumulation of HIF1α, where it dimerizes with HIF1β to form a
transcription factor. HIF1α upregulation, following transient,
mild levels of hypoxia is typically associated with cell survival and
proliferation56. During sustained hypoxia, however, HIF1α
induces apoptosis via a p53-dependent mechanism58. In FSHD
myoblasts, DUX4 inhibition of PAX7, resulting in HIF1α upre-
gulation, may mimic a sustained hypoxic response, resulting in
increased p53-mediated apoptosis.
To conclude, our ﬁndings indicate that DUX4 likely operates in
two ways to cause FSHD. Firstly, by driving the expression of a
cohort of transcriptional target genes, many of which are pro-
apoptotic, DUX4 can cause muscle pathology and cell death59.
Secondly, by perturbing the ability of PAX7 to activate/maintain
its transcriptional target genes, or by interfering with epigenetic
changes elicited by PAX7, DUX4 represses PAX7 transcriptional
target genes, likely causing pathology by mechanisms such as
HIF1α over-activation and aberrant epigenetic changes. Thus, we
propose that the model of FSHD molecular pathogenesis should
be updated to incorporate PAX7 target gene repression as an
important molecular mechanism and to reﬁne current ther-
apeutic strategies.
Methods
Published gene expression data. Publicly available gene expression data used in
this study fell into two distinct classes: data sets describing over-expression of Pax7
and DUX4, and data sets describing FSHD and control muscle biopsies. These ten
independent studies encompassed 222 samples: four studies10, 14, 33–35, totalling
35 samples described Pax7 and DUX4 over-expression. Six studies3, 10, 28, 30–32,
totalling 187 samples described FSHD and matched control muscle biopsies. Study
references, public database accession numbers, experimental design descriptions,
gene expression assay used and sample counts for each study are provided in
Supplementary Data 6. For the RNA-seq FSHD muscle biopsy study published by
Yao et al.10, we removed control sample C6 from our analysis as it was derived
from tibialis anterior, whereas all other samples in that study were isolated from
quadriceps.
Publicly available microarray studies were obtained log normalised, from the
GEO database. Quantile normalisation was subsequently performed across all
samples within each study. To enable comparison across data sets and evaluation of
the Pax7 and DUX4 scores, probes in each microarray data set and sequences in
the RNA-seq data were matched to unique gene identiﬁers (EntrezGene for human
and Ensemble for mouse). Probes or sequences mapping to the same gene identiﬁer
were averaged.
Microarray of Pax7 constructs. Procedures were carried out under the Animals
(Scientiﬁc Procedures) Act 1986, as approved by King’s College London Ethical
Review Process committee. Satellite cells were obtained from myoﬁbres isolated
from the extensor digitorum longus (EDL) muscles of three adult (6–8-week-old)
male C57BL/10 mice. Mice were killed by cervical dislocation and the EDL muscles
removed intact and incubated in 0.2% Collagenase Type 1 in Dulbecco's modiﬁed
Eagle medium (DMEM)-GlutaMAX (Invitrogen) at 37 °C for 90 min. Myoﬁbres
were then dissociated in DMEM-GlutaMAX under a stereo dissecting microscope
using a series of heat-polished glass Pasteur pipettes and rinsed in changes of
DMEM-GlutaMAX60. Intact myoﬁbres were plated on serum-reduced Matrigel
(BD) coated plates in proliferation medium (DMEM-GlutaMAX with 30% fetal
bovine serum (PAA), 10% horse serum (Gibco), 1% chick embryo extract (ICN
Flow), and 1% penicillin/streptomycin (Sigma)) at 37 °C and 5% CO260. Expanded
satellite cell-derived myoblasts were transduced with retroviral constructs encoding
Pax7 and dominant negative Pax7-ERD15 or control retroviruses using 4 μg/ml
Polybrene for 48 h. PAX7 is highly conserved, with 97% amino-acid sequence
similarity between mouse and human. RNA was isolated using RNeasy-mini col-
umns (Qiagen), processed using WT Gene Expression (Ambion) and GeneChip v4
Whole Transcript Sense Target Labelling Kit as per the manufacturers’ instruc-
tions, and hybridised to Mouse Gene Chip 1.0 ST arrays using the GCS3000
microarray system (Affymetrix). Array data were normalised using robust multi-
chip average (RMA), MvA transformation, and processed and statistically analysed
using Partek Genomics Suite software (Partek Inc.). Principal component analysis
on the 1000 most variable probes conﬁrmed validity of biological replicates.
Differential expression analysis. Differential gene expression analysis was per-
formed within two DUX4 over-expression studies17, 35 and our Pax7 construct
over-expression study to derive target gene sets. For microarray studies an
empirical Bayes approach was employed utilising the limma package in R61, while
for RNA-seq data the DESeq2 package62 was used to assess fold change. For
DUX4 studies, to replicate the approach used in previous analyses10, genes, which
showed log FC> 2 and FDR< 0.05 were considered signiﬁcantly upregulated by
DUX4. DUX4 target genes from the Choi et al.34 RNA-seq data and Geng et al.35
microarray data are displayed in Supplementary Data 1 and 2. For our Pax7
microarray study a slightly different approach was employed to take advantage of
the data from the dominant negative Pax7-ERD construct. Genes that showed both
a log FC> 1 and p< 0.05 under Pax7 transduction and a log FC < 1 and p< 0.05
under Pax7-ERD transduction, were considered induced by Pax7. Genes that
showed both a log FC < 1 and p< 0.05 under Pax7 transduction and a log FC> 1
and p < 0.05 under Pax7-ERD transduction, were considered repressed by Pax7:
listed in Supplementary Data 3.
Derivation and validation of Pax7 and DUX4 target genes. Three DUX4 target
gene scores were deﬁned corresponding to DUX4 activated targets derived from
the Yao et al.10, Choi et al.34 and Geng et al.35 DUX4 over-expression. For each
study, a single sample DUX4 target gene score was deﬁned as the average
expression of the DUX4 activated targets in a given sample.
Our Pax7 target gene score was deﬁned from our Pax7 construct microarray
derived induced and repressed targets (described above). A single sample
Pax7 score was then deﬁned as the t-statistic comparing the expression of induced
and repressed Pax7 targets within the sample, analogous to an approach we
previously employed63, 64. We validated our Pax7 score on a published data set14,
demonstrating that the score was signiﬁcantly elevated in Pax7-expressing samples
(p< 5 × 10−4, Supplementary Fig. 2).
Scores were z-normalised within each study, to reduce study-dependent effects,
and evaluation of score differences between FSHD and control samples in a single
study was performed via a Wilcoxon U-test.
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Meta-analysis of target gene scores. Meta-analysis to assess the discriminatory
powers of each of the target gene scores across the ﬁve microarray FSHD and
control muscle biopsy data sets, was performed using a random effects model to
combine statistics across studies. The p-values denoting the signiﬁcance of the
scores on meta-analysis were derived from a Fisher’s combined test.
ROC curve analysis was performed using the pROC package in R65.
GSEA of the target gene scores. GSEA was performed using a Fisher’s exact test
to compare Pax7 target gene sets against the gene sets deﬁned by the Molecular
Signatures Database37, 38. Computations were performed via software downloaded
from the Molecular Signatures database (http://www.broadinstitute.org/msigdb).
Human myoblast cell culture. Five immortalised human myoblast cell lines from
a mosaic FSHD1 patient 54-6, 54-A10 (control, 13 D4Z4 repeats) and 54-12,
54-A5, 54-2 (FSHD, 3 D4Z4 repeats)45, were kind gifts from Dr. Vincent Mouly
(Center for Research In Myology, UMRS 974 UPMC-INSERM, FRE 3617 CNRS,
Paris, France) and Professor Silvère der Maarel (Leiden University Medic’al Center,
Leiden, The Netherlands). Four immortalised human myoblast lines from two
FSHD1 patients and two sibling matched controls: 12Ubic, 12Abic, 16Ubic and
16Abic, were obtained from Professor Charles Emerson (UMMS Wellstone centre
for FSHD, Worcester, MA, USA)44. Immortalised human myoblasts were cultured
in Skeletal Muscle Cell Growth Medium (Promocel) supplemented with 20% fetal
bovine serum, 50 μg/ml Fetuin (bovine), 10 ng/ml epidermal growth factor
(recombinant human), 1 ng/ml basic ﬁbroblast growth factor (recombinant
human), 10 μg/ml insulin (recombinant human), 0.4 μg/ml dexamethasone and 50
μg/ml gentamycin, at 37 °C under 5% CO2. RNA was harvested from proliferating
myoblasts as they reached conﬂuency for each line in triplicate using RNeasy kit
(Qiagen) according to the manufacturer’s recommendation, including an addi-
tional DNA removal step using RNase-Free DNase Set (Qiagen).
RNA seq and alignment. RNA-seq libraries were prepared using the Agilent
sureselect stranded RNAseq protocol, which allows polyA selection but was
modiﬁed to work with ribodepletion. Prepared libraries were sequenced on an
Illumina HiSeq2500. The raw reads were trimmed using trim-galore, utilising
cutadapt66 (v0.4.0) to remove the Illumina Sequencing Adapter (AGATCGGAAG
AGC) at the 3′-end. Additionally, 12 bases were also trimmed from the 5′-end of
the reads since they showed a biased distribution of bases. The reads were mapped
to the human transcriptome using the human genome sequence GRCh38 and v82
gene annotations downloaded from Ensembl. The mapping was performed using
tophat67 (v2.1.0) and bowtie68 (v1.1.0), enabling the fr-ﬁrststrand option of tophat
to restrict mapping to the sense strand of the transcript. Reads were assigned to
genes using the featureCounts program69 (v1.5.0), counting fragments and
ignoring multi-mapping reads. Gene assignment was also restricted so to the sense
strand of the transcript. The resulting matrix of read counts was then loaded into R
and normalised using DESeq262 before computation of Pax7 and DUX4 target gene
scores.
Reporter gene assays. HEK-293 or NIH-3T3 cells (12,500 cells/well) were
transfected with pMSCV-IRES-eGFP plasmids encoding DUX4 and/or Pax7, or
dominant negative DUX4-ERD, or dominant negative Pax7-ERD15, 29, together
with reporter plasmids encoding either DUX4-responsive promoters driving luci-
ferase expression (pZSCAN4-luc35 or RFPL4B-luc) or a Pax3/7-responsive element
driving β-galactosidase (p34 plasmid15) using Lipofectamin LTX (Thermoﬁsher). A
pRSV vector encoding either β-galactosidase or luciferase as appropriate was co-
transfected as an internal control for normalisation of transfection efﬁciency. Total
amount of DNA transfected per reaction was 1.5 mg, in equal ratios for reporters
and plasmids encoding genes of interest, and 250 ng/reaction of the internal nor-
maliser vector. Cells were harvested 24 h after transfection, and assayed using the
Dual-light Reporter system (Thermoﬁsher) according to the manufacturer’s
instructions. 3-4 independent transfections were performed in technical triplicate.
Reporter gene activity was measured using Glomax-Multi + plate reader (Promega)
and normalised for transfection efﬁciency. N = 3/4 for each cell line, analysis of
variance (ANOVA) revealed signiﬁcant intensity differences, post hoc unpaired
two-tailed t-tests were employed to assess signiﬁcant pairwise differences.
Reverse transcription quantitative PCR. HEK-293 (150 000 cells/well) were
transfected with plasmids encoding DUX4 and/or Pax7, or dominant negative
DUX4-ERD, or dominant negative Pax7-ERD15, 29. RNA was isolated after 24 h and
reverse-transcribed using the Reverse Transcription Kit with genomic DNA
wipeout (Qiagen); RT-qPCR was performed on a Viia7 qPCR system (Life Tech-
nologies) with MESA Blue qPCR MasterMix Plus and ROX reference dye (Euro-
gentec). Primers used were as follows:
RPLPO (FWD: 5′-TCTACAACCCTGAAGTGCTTGAT-3′, REV: 5′-CAATC
TGCAGACAGACACTGG-3′)
ZSCAN4 (FWD: 5′-TGGAAATCAAGTGGCAAAAA-3′, REV: 5′-CTGCATG
TGGACGTGGAC-3′)
TRIM48 (FWD: 5′-TGAATGTGGAAACCACCAGA-3′, REV: 5′-GTTGAGC
CTGTCCCTCAGTC-3′)
RFPL4B (FWD: 5′-GAGACGTAGGCTTCGGATCTT-3′, REV: 5′-GGCTGA
ATTCAAGTGGGTCT-3′)
MBD3L2 (FWD: 5′-GCGTTCACCTCTTTTCCAAG-3′, REV: 5′-GCCATGT
GGATTTCTCGTTT-3′)
SELP (FWD: 5′-CGCCTGCCTCCAGACCATCTTC-3′, REV: 5′-CTATTCA
CATTCCAGAAACTCACCACAGC-3′)
Data availability. Microarray and RNA-seq data are available from the GEO data
base (https://www.ncbi.nlm.nih.gov/geo/), accession numbers GSE77478 (micro-
array) and GSE102812 (RNA-seq).
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